FORM 4

Check this box if no longe Section 16. Form 4 or For

obligations may continue. Instruction 1(b).

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D	D.C. 20549
---------------	------------

r subject to m 5	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
See	

**OMB APPROVAL** OMB Number: 3235-0287 Estimated average burden hours per response:

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Schobel Alexander Mark						2. Issuer Name and Ticker or Trading Symbol Aquestive Therapeutics, Inc. [ AQST ]									eck all appli Direct	ationship of Reportin k all applicable) Director Officer (give title		son(s) to Iss 10% Ov Other (s	vner
(Last) (First) (Middle) C/O AQUESTIVE THERAPEUTICS, INC. 30 TECHNOLOGY DRIVE						3. Date of Earliest Transaction (Month/Day/Year) 06/30/2020										below) below)  Chief Innovation/Tech Officer			
(Street) WARRE (City)			07059 (Zip)		4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filin Line)  X Form filed by One Representies the Person											e Repo	porting Person	
		Tabl	e I - Nor	n-Deriv	ative	Sec	curitie	es Ac	quired,	Dis	posed (	of, or I	Bene	ficial	ly Owne	d			
I - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -			2. Transa Date (Month/E	Execution Date,			3. Transa Code r) 8)		4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)				Benefic Owned	es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
								Code	v	Amount	(A (D	or	Price	Reporte Transac (Instr. 3	tion(s)			(Instr. 4)	
Common	Common Stock 0				06/30/2020				M <sup>(1)</sup>		333		A	\$0	912	2,886	D		
Common Stock 06/30					/2020				<b>F</b> <sup>(2)</sup>		94 D		D	\$4.80	5 912	2,792	D		
		Т									osed of onverti				Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/Da	Date, Transa Code (I					6. Date Ex Expiration (Month/Da	Date	Amount o		t of ies ring ive Sec		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				c	Code	v	(A)		Date Exercisal		xpiration ate	Title	or Nu of	ımber					
Restricted Stock	\$0	06/30/2020			<b>M</b> <sup>(1)</sup>			333	06/30/202	20	(3)	Commo		333	\$0	0		D	

## Explanation of Responses:

- 1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- 2. These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock award. The amount retained by the Company was not in excess of the amount of the tax liability.
- 3. There are no expiration dates on RSUs.

## Remarks:

/s/ Robert Arnold, as Attorney-In-Fact

\*\* Signature of Reporting Person

07/02/2020

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.